Erratum: Genomics and susceptibility profiles of extensively drug-resistant pseudomonas aeruginosa isolates from Spain (Antimicrobial Agents and Chemotherapy (2017) 61:11 (e01589-17) DOI: 10.1128/AAC.01589-17);Genomics and susceptibility profiles of extensively drug-resistant pseudomonas aeruginosa isolates from Spain

Antimicrobial Agents and Chemotherapy

Volumn 61, Issue 11, 2017, Pages

  Del Barrio Tofiño, Ester ^a   López Causapé, Carla ^a   Cabot, Gabriel ^a   Rivera, Alba ^b   Benito, Natividad ^b   Segura, Concepción ^c   Montero, María Milagro ^c   Sorlí, Luisa ^c   Tubau, Fe ^d   Gómez Zorrilla, Silvia ^d   Tormo, Nuria ^e   Durá Navarro, Raquel ^e   Viedma, Esther ^f   Resino Foz, Elena ^f   Fernández Martínez, Marta ^g   González Rico, Claudia ^g   Alejo Cancho, Izaskun ^d   Martínez, Jose Antonio ^d   Labayru Echverria, Cristina ^h   Dueñas, Carlos ^h   Ayestarán, Ignacio ^a   Zamorano, Laura ^a   Martinez Martinez, Luis ^i,j   Horcajada, Juan Pablo ^c   Oliver, Antonio ^a   more..

^a HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

^b HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^c HOSPITAL DEL MAR   (Spain)

^d HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^e HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

^f HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^g HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^h HOSPITAL UNIVERSITARIO DE BURGOS   (Spain)

ⁱ HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^j Instituto de Salud Carlos III   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AZTREONAM; CEFEPIME; CEFTAZIDIME; CEFTOLOZANE PLUS TAZOBACTAM; CIPROFLOXACIN; COLISTIN; FOSFOMYCIN; IMIPENEM; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; POLYMYXIN; TOBRAMYCIN; AMINOGLYCOSIDE; AMPC BETA-LACTAMASES; ANTIINFECTIVE AGENT; BACTERIAL PROTEIN; BETA LACTAMASE; CEFTOLOZANE, TAZOBACTAM DRUG COMBINATION; CEPHALOSPORIN DERIVATIVE; PENICILLANIC ACID; QUINOLONE DERIVATIVE;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; BLOODSTREAM INFECTION; CONTROLLED STUDY; GENE MUTATION; GENOMICS; INDEL MUTATION; MISMATCH REPAIR; MISSENSE MUTATION; MULTILOCUS SEQUENCE TYPING; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; PULSED FIELD GEL ELECTROPHORESIS; SPAIN; ANALOGS AND DERIVATIVES; ANTIBIOTIC RESISTANCE; BETA-LACTAM RESISTANCE; DRUG EFFECT; GENETICS; HUMAN; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MOLECULAR EPIDEMIOLOGY; PSEUDOMONAS INFECTION;

AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BETA-LACTAM RESISTANCE; BETA-LACTAMASES; CEPHALOSPORINS; DRUG RESISTANCE, BACTERIAL; FLUOROQUINOLONES; HUMANS; MICROBIAL SENSITIVITY TESTS; MOLECULAR EPIDEMIOLOGY; PENICILLANIC ACID; POLYMYXINS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; SPAIN;

EID: 85032468119     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02352-17     Document Type: Erratum

References (78)

1. Livermore MD. 2009. Has the era of untreatable infections arrived? J Antimicrob Chemother 64(Suppl 1):29–36. https://doi.org/10.1093/jac/dkp255.
2. Mesaros N, Nordmann P, Plésiat P, Roussel-Delvallez M, Van Eldere J, Glupczynski Y, Van Laethem Y, Jacobs F, Lebecque P, Malfroot A, Tulkens PM, Van Bambeke F. 2007. Pseudomonas aeruginosa: resistance and therapeutic options at the turn of the new millennium. Clin Microbiol Infect 13:560 –578. https://doi.org/10.1111/j.1469-0691.2007.01681.x.
3. Peña C, Suarez C, Gozalo M, Murillas J, Almirante B, Pomar V, Aguilar M, Granados A, Calbo E, Rodríguez-Baño J, Rodríguez F, Tubau F, Martínez-Martínez L, Oliver A, Spanish Network for Research in Infectious Diseases REIPI. 2012. Prospective multicenter study of the impact of carbapenem resistance on mortality in Pseudomonas aeruginosa bloodstream infections. Antimicrob Agents Chemother 56:1265–1272. https://doi.org/10.1128/AAC.05991-11.
4. Lister PD, Wolter DJ, Hanson ND. 2009. Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromo-somally encoded resistance mechanisms. Clin Microbiol Rev 22:582– 610. https://doi.org/10.1128/CMR.00040-09.
5. Poole K. 2011. Pseudomonas aeruginosa: resistance to the max. Front Microbiol 5:2–65. https://doi.org/10.3389/fmicb.2011.00065.
6. Woodford N, Turton JF, Livermore DM. 2011. Multiresistant Gram-negative bacteria: the role of high-risk clones in the dissemination of antibiotic resistance. FEMS Microbiol Rev 35:736–755. https://doi.org/10.1111/j.1574-6976.2011.00268.x.
7. Oliver A, Mulet X, López-Causapé C, Juan C. 2015. The increasing threat of Pseudomonas aeruginosa high-risk clones. Drug Resist Updat 21-22: 41–59.
8. Cabot G, López-Causapé C, Ocampo-Sosa AA, Sommer LM, Domínguez MÁ Zamorano L, Juan C, Tubau F, Rodríguez C, Moyá B, Peña C, Martínez-Martínez L, Plesiat P, Oliver A. 2016. Deciphering the resistome of the widespread Pseudomonas aeruginosa sequence type 175 international high-risk clone through whole-genome sequencing. Antimicrob Agents Chemother 60:7415–7423. https://doi.org/10.1128/AAC.02676-15.
9. Jeukens J, Freschi L, Kukavica-Ibrulj I, Emond-Rheault JG, Tucker NP, Levesque RC. 2 June 2017. Genomics of antibiotic-resistance prediction in Pseudomonas aeruginosa. Ann N Y Acad Sci https://doi.org/10.1111/nyas.13358.
10. Treepong P, Kos VN, Guyeux C, Blanc DS, Bertrand X, Valot B, Hocquet D. 22 June 2017. Global emergence of the widespread Pseudomonas aeruginosa ST235 clone. Clin Microbiol Infect https://doi.org/10.1016/j.cmi.2017.06.018.
11. Jaillard M, van Belkum A, Cady KC, Creely D, Shortridge D, Blanc B, Barbu EM, Dunne WM, Jr, Zambardi G, Enright M, Mugnier N, Le Priol C, Schicklin S, Guigon G, Veyrieras JB. 2017. Correlation between phenotypic antibiotic susceptibility and the resistome in Pseudomonas aeruginosa. Int J Antimicrob Agents 50:210–218. https://doi.org/10.1016/j.ijantimicag.2017.02.026.
12. Kos VN, Déraspe M, McLaughlin RE, Whiteaker JD, Roy PH, Alm RA, Corbeil J, Gardner H. 2015. The resistome of Pseudomonas aeruginosa in relationship to phenotypic susceptibility. Antimicrob Agents Chemother 59:427– 436. https://doi.org/10.1128/AAC.03954-14.
13. Turton JF, Wright L, Underwood A, Witney AA, Chan YT, Al-Shahib A, Arnold C, Doumith M, Patel B, Planche TD, Green J, Holliman R, Woodford N. 2015. High-resolution analysis by whole-genome sequencing of an international lineage (sequence type 111) of Pseudomonas aeruginosa associated with metallo-carbapenemases in the United Kingdom. J Clin Microbiol 53:2622–2631. https://doi.org/10.1128/JCM.00505-15.
14. Moyá B, Zamorano L, Juan C, Pérez JL, Ge Y, Oliver A. 2010. Activity of a new cephalosporin, CXA-101 (FR264205), against beta-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients. Antimicrob Agents Chemother 54:1213–1217. https://doi.org/10.1128/AAC.01104-09.
15. Moyá B, Beceiro A, Cabot G, Juan C, Zamorano L, Alberti S, Oliver A. 2016. Pan--lactam resistance development in Pseudomonas aeruginosa clinical strains: molecular mechanisms, penicillin-binding protein profiles, and binding affinities. Antimicrob Agents Chemother 56:4771– 4778.
16. van Duin D, Bonomo RA. 2016. Ceftazidime/avibactam and ceftolozane/ tazobactam: second-generation -lactam/-lactamase inhibitor combination. Clin Infect Dis 63:234–241. https://doi.org/10.1093/cid/ciw243.
17. Haidar G, Philips NJ, Shields RK, Snyder D, Cheng S, Potoski BA, Doi Y, Hao B, Press EG, Cooper VS, Clancy CJ, Nguyen MH. 2017. Ceftolozane-tazobactam for the treatment of multidrug-resistant Pseudomonas aeruginosa infections: clinical effectiveness and evolution of resistance. Clin Infect Dis 65:110–120. https://doi.org/10.1093/cid/cix182.
18. Munita JM, Aitken SL, Miller WR, Perez F, Rosa R, Shimose LA, Lichten-berger PN, Abbo LM, Jain R, Nigo M, Wanger A, Araos R, Tran TT, Adachi J, Rakita R, Shelburne S, Bonomo RA, Arias CA. 2017. Multicenter evaluation of ceftolozane/tazobactam for serious infections caused by carbapenem-resistant Pseudomonas aeruginosa. Clin Infect Dis 65: 158–161. https://doi.org/10.1093/cid/cix014.
19. Castanheira M, Mills JC, Farrell DJ, Jones RN. 2014. Mutation-driven -lactam resistance mechanisms among contemporary ceftazidime-nonsusceptible Pseudomonas aeruginosa isolates from U.S. hospitals. Antimicrob Agents Chemother 58:6844–6850. https://doi.org/10.1128/AAC.03681-14.
20. Oliver A, Cantón R, Campo P, Baquero F, Blázquez J. 2000. High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection. Science 288:1251–1254. https://doi.org/10.1126/science.288.5469.1251.
21. López-Causapé C, Sommer LM, Cabot G, Rubio R, Ocampo-Sosa AA, Johansen HK, Figuerola J, Cantón R, Kidd TJ, Molin S, Oliver A. 2017. Evolution of the Pseudomonas aeruginosa mutational resistome in an international cystic fibrosis clone. Sci Rep 7:5555. https://doi.org/10.1038/s41598-017-05621-5.
22. Kidd TJ, Grimwood K, Ramsay KA, Rainey P, Bell SC. 2011. Comparison of three molecular techniques for typing Pseudomonas aeruginosa isolates in sputum samples. J Clin Microbiol 49:263–268. https://doi.org/10.1128/JCM.01421-10.
23. García-Castillo M, Máiz L, Morosini MI, Rodríguez-Baños M, Suarez L, Fernández-Olmos A, Baquero F, Cantón R, del Campo R. 2012. Emergence of a mutL mutation causing multilocus sequence typing-pulsed-field gel electrophoresis discrepancy among Pseudomonas aeruginosa isolates from a cystic fibrosis patient. J Clin Microbiol 50:1777–1778. https://doi.org/10.1128/JCM.05478-11.
24. López-Causapé C, Rojo-Molinero E, Mulet X, Cabot G, Moyá B, Figuerola J, Togores B, Pérez JL, Oliver A. 2013. Clonal dissemination, emergence of mutator lineages and antibiotic resistance evolution in Pseudomonas aeruginosa cystic fibrosis chronic lung infection. PLoS One 8:e71001. https://doi.org/10.1371/journal.pone.0071001.
25. Mena A, Smith EE, Burns JL, Speert DP, Moskowitz SM, Perez JL, Oliver A. 2008. Genetic adaptation of Pseudomonas aeruginosa to the airways of cystic fibrosis patients is catalyzed by hypermutation. J Bacteriol 190: 7910–7917. https://doi.org/10.1128/JB.01147-08.
26. Cabot G, Ocampo-Sosa AA, Domínguez MA, Gago JF, Juan C, Tubau F, Rodríguez C, Moyá B, Peña C, Martínez-Martínez L, Oliver A, Spanish Network for Research in Infectious Diseases (REIPI). 2012. Genetic markers of widespread extensively drug-resistant Pseudomonas aeruginosa high-risk clones. Antimicrob Agents Chemother 56:6349–6357. https://doi.org/10.1128/AAC.01388-12.
27. Mulet X, Cabot G, Ocampo-Sosa AA, Domínguez MA, Zamorano L, Juan C, Tubau F, Rodríguez C, Moyá B, Peña C, Martínez-Martínez L, Oliver A, Spanish Network for Research in Infectious Diseases (REIPI). 2013. Biological markers of Pseudomonas aeruginosa epidemic high-risk clones. Antimicrob Agents Chemother 57:5527–5535. https://doi.org/10.1128/AAC.01481-13.
28. Peña C, Cabot G, Gómez-Zorrilla S, Zamorano L, Ocampo-Sosa A, Murillas J, Almirante B, Pomar V, Aguilar M, Granados A, Calbo E, Rodríguez-Baño J, Rodríguez-López F, Tubau F, Martínez-Martínez L, Oliver A, Spanish Network for Research in Infectious Diseases (REIPI). 2015. Influence of virulence genotype and resistance profile in the mortality of Pseudomonas aeruginosa bloodstream infections. Clin Infect Dis 60:539 –548. https://doi.org/10.1093/cid/ciu866.
29. Castanheira M, Deshpande LM, Costello A, Davies TA, Jones RN. 2014. Epidemiology and carbapenem resistance mechanisms of carbapenem-non-susceptible Pseudomonas aeruginosa collected during 2009–11 in 14 European and Mediterranean countries. J Antimicrob Chemother 69:1804–1814. https://doi.org/10.1093/jac/dku048.
30. Cholley P, Thouverez M, Hocquet D, van der Mee-Marquet N, Talon D, Bertrand X. 2011. Most multidrug-resistant Pseudomonas aeruginosa isolates from hospitals in eastern France belong to a few clonal types. J Clin Microbiol 49:2578–2583. https://doi.org/10.1128/JCM.00102-11.
31. Guzvinec M, Izdebski R, Butic I, Jelic M, Abram M, Koscak I, Baraniak A, Hryniewicz W, Gniadkowski M, Tambic Andrasevic A. 2014. Sequence types 235, 111, and 132 predominate among multidrug-resistant Pseudomonas aeruginosa clinical isolates in Croatia. Antimicrob Agents Chemother 58:6277–6283. https://doi.org/10.1128/AAC.03116-14.
32. Mano Y, Saga T, Ishii Y, Yoshizumi A, Bonomo RA, Yamaguchi K, Tateda K. 2015. Molecular analysis of the integrons of metallo- -lactamase-producing Pseudomonas aeruginosa isolates collected by nationwide surveillance programs across Japan. BMC Microbiol 15:41. https://doi.org/10.1186/s12866-015-0378-8.
33. Wright LL, Turton JF, Livermore DM, Hopkins KL, Woodford N. 2015. Dominance of international ‘high-risk clones’ among metallo--lactamase-producing Pseudomonas aeruginosa in the UK. J Antimicrob Chemother 70:103–110. https://doi.org/10.1093/jac/dku339.
34. Feng W, Sun F, Wang Q, Xiong W, Qiu X, Dai X, Xia P. 2017. Epidemiology and resistance characteristics of Pseudomonas aeruginosa isolates from the respiratory department of a hospital in China. J Glob Antimicrob Resist 8:142–147. https://doi.org/10.1016/j.jgar.2016.11.012.
35. Moya B, Dötsch A, Juan C, Blázquez J, Zamorano L, Haussler S, Oliver A. 2009. Beta-lactam resistance response triggered by inactivation of a nonessential penicillin-binding protein. PLoS Pathog 5:e1000353. https://doi.org/10.1371/journal.ppat.1000353.
36. Cabot G, Bruchmann S, Mulet X, Zamorano L, Moyà B, Juan C, Haussler S, Oliver A. 2014. Pseudomonas aeruginosa ceftolozane-tazobactam resistance development requires multiple mutations leading to overexpression and structural modification of AmpC. Antimicrob Agents Chemother 58:3091–3099. https://doi.org/10.1128/AAC.02462-13.
37. Lahiri SD, Johnstone MR, Ross PL, McLaughlin RE, Olivier NB, Alm RA. 2014. Avibactam and class C -lactamases: mechanism of inhibition, conservation of the binding pocket, and implications for resistance. Antimicrob Agents Chemother 58:5704–5713. https://doi.org/10.1128/AAC.03057-14.
38. Haidar G, Clancy CJ, Chen L, Samanta P, Shields RK, Kreiswirth BN, Nguyen MH. 2017. Identifying spectra of activity and therapeutic niches for ceftazidime-avibactam and imipenem-relebactam against carbapenem-resistant Enterobacteriaceae. Antimicrob Agents Chemother 61:e00642-17. https://doi.org/10.1128/AAC.00642-17.
39. Fraile-Ribot PA, Mulet X, Cabot G, Del Barrio-Tofiño E, Juan C, Pérez JL, Oliver A. 2017. In vivo emergence of resistance to novel cephalosporin--lactamase inhibitor combinations through the duplication of the amino acid D149 from OXA-2 -lactamase (OXA-539) in ST235 Pseudomonas aeruginosa. Antimicrob Agents Chemother 61:e01117-17.
40. Berrazeg M, Jeannot K, Ntsogo Enguéné VY, Broutin I, Loeffert S, Fournier D, Plésiat P. 2015. Mutations in -lactamase AmpC increase resistance of Pseudomonas aeruginosa isolates to antipseudomonal cephalosporins. Antimicrob Agents Chemother 59:6248 – 6255. https://doi.org/10.1128/AAC.00825-15.
41. Chen W, Zhang YM, Davies C. 2016. Penicillin-binding protein 3 is essential for growth of Pseudomonas aeruginosa. Antimicrob Agents Chemother 61:e01651-16. https://doi.org/10.1128/AAC.01651-16.
42. Diaz Caballero J, Clark ST, Coburn B, Zhang Y, Wang PW, Donaldson SL, Tullis DE, Yau YC, Waters VJ, Hwang DM, Guttman DS. 2015. Selective sweeps and parallel pathoadaptation drive Pseudomonas aeruginosa evolution in the cystic fibrosis lung. mBio 6:e00981-15. https://doi.org/10.1128/mBio.00981-15.
43. Cabot G, Zamorano L, Moyá B, Juan C, Navas A, Blázquez J, Oliver A. 2016. Evolution of Pseudomonas aeruginosa antimicrobial resistance and fitness under low and high mutation rates. Antimicrob Agents Chemother 60:1767–1778. https://doi.org/10.1128/AAC.02676-15.
44. Han S, Zaniewski RP, Marr ES, Lacey BM, Tomaras AP, Evdokimov A, Miller JR, Shanmugasundaram V. 2010. Structural basis for effectiveness of siderophore-conjugated monocarbams against clinically relevant strains of Pseudomonas aeruginosa. Proc Natl Acad Sci U S A 107:22002–22007. https://doi.org/10.1073/pnas.1013092107.
45. Bruchmann S, Dötsch A, Nouri B, Chaberny IF, Häussler S. 2013. Quantitative contributions of target alteration and decreased drug accumulation to Pseudomonas aeruginosa fluoroquinolone resistance. Antimicrob Agents Chemother 57:1361–1368. https://doi.org/10.1128/AAC.01581-12.
46. Maciá MD, Borrell N, Segura M, Gómez C, Pérez JL, Oliver A. 2006. Efficacy and potential for resistance selection of antipseudomonal treatments in a mouse model of lung infection by hypermutable Pseudomonas aeruginosa. Antimicrob Agents Chemother 50:975–983. https://doi.org/10.1128/AAC.50.3.975-983.2006.
47. Reinhardt A, Köhler T, Wood P, Rohner P, Dumas JL, Ricou B, van Delden C. 2007. Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. Antimicrob Agents Chemother 51:1341–1350. https://doi.org/10.1128/AAC.01278-06.
48. Marvig RL, Sommer LM, Molin S, Johansen HK. 2015. Convergent evolution and adaptation of Pseudomonas aeruginosa within patients with cystic fibrosis. Nat Genet 47:57–64. https://doi.org/10.1038/ng.3148.
49. Prickett MH, Hauser AR, McColley SA, Cullina J, Potter E, Powers C, Jain M. 2017. Aminoglycoside resistance of Pseudomonas aeruginosa in cystic fibrosis results from convergent evolution in the mexZ gene. Thorax 72:40 – 47. https://doi.org/10.1136/thoraxjnl-2015-208027.
50. Feng Y, Jonker MJ, Moustakas I, Brul S, Ter Kuile BH. 2016. Dynamics of mutations during development of resistance by Pseudomonas aeruginosa against five antibiotics. Antimicrob Agents Chemother 60: 4229–4236. https://doi.org/10.1128/AAC.00434-16.
51. Schurek KN, Marr AK, Taylor PK, Wiegand I, Semenec L, Khaira BK, Hancock RE. 2008. Novel genetic determinants of low-level aminoglycoside resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother 52:4213–4219. https://doi.org/10.1128/AAC.00507-08.
52. El’Garch F, Jeannot K, Hocquet D, Llanes-Barakat C, Plésiat P. 2007. Cumulative effects of several nonenzymatic mechanisms on the resistance of Pseudomonas aeruginosa to aminoglycosides. Antimicrob Agents Chemother 51:1016 –1021. https://doi.org/10.1128/AAC.00704-06.
53. Bergen PJ, Landersdorfer CB, Lee HJ, Li J, Nation RL. 2012. ‘Old’ antibiotics for emerging multidrug-resistant bacteria. Curr Opin Infect Dis 25:626–633. https://doi.org/10.1097/QCO.0b013e328358afe5.
54. Morita Y, Tomida J, Kawamura Y. 2014. Responses of Pseudomonas aeruginosa to antimicrobials. Front Microbiol 4:422. https://doi.org/10.3389/fmicb.2013.00422.
55. Tomaras AP, McPherson CJ, Kuhn M, Carifa A, Mullins L, George D, Desbonnet C, Eidem TM, Montgomery JI, Brown MF, Reilly U, Miller AA, O’Donnell JP. 2014. LpxC inhibitors as new antibacterial agents and tools for studying regulation of lipid biosynthesis in Gram-negative pathogens. mBio 5(5):e01551-14. https://doi.org/10.1128/mBio.01551-14.
56. Gutu AD, Sgambati N, Strasbourger P, Brannon MK, Jacobs MA, Haugen E, Kaul RK, Johansen HK, Høiby N, Moskowitz SM. 2013. Polymyxin resistance of Pseudomonas aeruginosa phoQ mutants is dependent on additional two-component regulatory systems. Antimicrob Agents Chemother 57:2204–2215. https://doi.org/10.1128/AAC.02353-12.
57. Fernández L, Jenssen H, Bains M, Wiegand I, Gooderham WJ, Hancock RE. 2012. The two-component system CprRS senses cationic peptides and triggers adaptive resistance in Pseudomonas aeruginosa independently of ParRS. Antimicrob Agents Chemother 56:6212–6222. https://doi.org/10.1128/AAC.01530-12.
58. Moskowitz SM, Brannon MK, Dasgupta N, Pier M, Sgambati N, Miller AK, Selgrade SE, Miller SI, Denton M, Conway SP, Johansen HK, Høiby N. 2012. PmrB mutations promote polymyxin resistance of Pseudomonas aeruginosa isolated from colistin-treated cystic fibrosis patients. Antimicrob Agents Chemother 56:1019 –1030. https://doi.org/10.1128/AAC.05829-11.
59. Miller AK, Brannon MK, Stevens L, Johansen HK, Selgrade SE, Miller SI, Høiby N, Moskowitz SM. 2011. PhoQ mutations promote lipid A modification and polymyxin resistance of Pseudomonas aeruginosa found in colistin-treated cystic fibrosis patients. Antimicrob Agents Chemother 55:5761–5769. https://doi.org/10.1128/AAC.05391-11.
60. Lee JY, Chung ES, Na IY, Kim H, Shin D, Ko KS. 2014. Development of colistin resistance in pmrA-, phoP-, parR- and cprR-inactivated mutants of Pseudomonas aeruginosa. J Antimicrob Chemother 69:2966 –2971. https://doi.org/10.1093/jac/dku238.
61. Asuphon O, Montakantikul P, Houngsaitong J, Kiratisin P, Sonthisombat P. 2016. Optimizing intravenous fosfomycin dosing in combination with carbapenems for treatment of Pseudomonas aeruginosa infections in critically ill patients based on pharmacokinetic/pharmacodynamic (PK/ PD) simulation. Int J Infect Dis 50:23–29. https://doi.org/10.1016/j.ijid.2016.06.017.
62. Castañeda-García A, Rodríguez-Rojas A, Guelfo JR, Blázquez J. 2009. The glycerol-3-phosphate permease GlpT is the only fosfomycin transporter in Pseudomonas aeruginosa. J Bacteriol 191:6968–6974. https://doi.org/10.1128/JB.00748-09.
63. Edelstein MV, Skleenova EN, Shevchenko OV, D’souza JW, Tapalski DV, Azizov IS, Sukhorukova MV, Pavlukov RA, Kozlov RS, Toleman MA, Walsh TR. 2013. Spread of extensively resistant VIM-2-positive ST235 Pseudomonas aeruginosa in Belarus, Kazakhstan, and Russia: a longitudinal epidemiological and clinical study. Lancet Infect Dis 13:867– 876. https:// doi.org/10.1016/S1473-3099(13)70168-3.
64. Juan C, Zamorano L, Pérez JL, Ge Y, Oliver A. 2010. Activity of a new antipseudomonal cephalosporin, CXA-101 (FR264205), against carbapenem-resistant and multidrug-resistant Pseudomonas aeruginosa clinical strains. Antimicrob Agents Chemother 54:846–851. https://doi.org/10.1128/AAC.00834-09.
65. CLSI. 2017. Performance standards for antimicrobial susceptibility testing, 27th ed, vol 37. CLSI document M100. Clinical and Laboratory Standards Institute, Wayne, PA.
66. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, Harbarth S, Hindler JF, Kahlmeter G, Olsson-Liljequist B, Paterson DL, Rice LB, Stelling J, Struelens MJ, Vatopoulos A, Weber JT, Monnet DL. 2012. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 18:268–281. https://doi.org/10.1111/j.1469-0691.2011.03570.x.
67. Kaufmann ME. 1998. Pulsed-field gel electrophoresis. Methods Mol Med 15:33–50. https://doi.org/10.1385/0-89603-498-4:33.
68. Tenover FC, Arbeit RD, Goering RV, Mickelsen A, Murray BE, Persing DH, Swaminathan B. 1995. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J Clin Microbiol 33:2233–2239.
69. Mikucionyte G, Zamorano L, Vitkauskiene A, López-Causapé C, Juan C, Mulet X, Oliver A. 2016. Nosocomial dissemination of VIM-2-producing ST235 Pseudomonas aeruginosa in Lithuania. Eur J Clin Microbiol Infect Dis 35:195–200. https://doi.org/10.1007/s10096-015-2529-0.
70. Juan C, Moyá B, Pérez JL, Oliver A. 2006. Stepwise upregulation of the Pseudomonas aeruginosa chromosomal cephalosporinase conferring high-level beta-lactam resistance involves three AmpD homologues. Antimicrob Agents Chemother 50:1780–1787. https://doi.org/10.1128/AAC.50.5.1780-1787.2006.
71. Cabot G, Ocampo-Sosa AA, Tubau F, Macia MD, Rodríguez C, Moya B, Zamorano L, Suárez C, Peña C, Martínez-Martínez L, Oliver A, Spanish Network for Research in Infectious Diseases (REIPI). 2011. Overexpression of AmpC and efflux pumps in Pseudomonas aeruginosa isolates from bloodstream infections: prevalence and impact on resistance in a Spanish multicenter study. Antimicrob Agents Chemother 55:1906 –1911. https://doi.org/10.1128/AAC.01645-10.
72. Marvig RL, Johansen HK, Molin S, Jelsbak L. 2013. Genome analysis of a transmissible lineage of Pseudomonas aeruginosa reveals pathoadaptive mutations and distinct evolutionary paths of hypermutators. PLoS Genet 9:e1003741. https://doi.org/10.1371/journal.pgen.1003741.
73. Langmead B, Salzberg SL. 2012. Fast gapped-read alignment with Bowtie 2. Nat Methods 9:357–359. https://doi.org/10.1038/nmeth.1923.
74. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, Marth G, Abecasis G, Durbin R, 1000 Genome Project Data Processing Subgroup. 2009. The Sequence Alignment/Map format and SAMtools. Bioinformat-ics 25:2078–2079. https://doi.org/10.1093/bioinformatics/btp352.
75. DePristo MA, Banks E, Poplin R, Garimella KV, Maguire JR, Hartl C, Phillippakis AA, del Angel G, Rivas MA, Hanna M, McKenna A, Fennell TJ, Kernytsky AM, Sivachenko AY, Cibulskis K, Gabriel SB, Altshuler D, Daly MJ. 2011. A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat Genet 43:491–498. https://doi.org/10.1038/ng.806.
76. Zerbino DR, Birney E. 2008. Velvet: algorithms for de novo short read assembly using de Bruijn graphs. Genome Res 18:821–829. https://doi.org/10.1101/gr.074492.107.
77. Cingolani P, Platts A, Wang le L, Coon M, Nguyen T, Wang L, Land SJ, Lu X, Ruden DM. A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of Drosophila melanogaster strain w1118; iso-2; iso-3. Fly (Austin) 6:80–92.
78. Zankari E, Hasman H, Cosentino S, Vestergaard M, Rasmussen S, Lund O, Aarestrup FM, Larsen MV. 2012. Identification of acquired antimicrobial resistance genes. J Antimicrob Chemother 67:2640–2644. https://doi.org/10.1093/jac/dks261.